---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123324"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:35:43.434859+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma Q3 net loss $28.7M; LIFT-AD missed endpoints; exploring strategic alternatives

## Summary
- Net loss $28.7M ($0.75/sh) vs $33.0M ($0.87/sh) Q3 2023; cash $68.9M down from $147.4M at Dec 2023.
- Fosgonimeton (ATH-1017) LIFT-AD Phase 2/3 missed primary and key secondary endpoints; development paused.
- Exploring strategic alternatives with Cantor Fitzgerald; ATH-1105 Phase 1 healthy volunteers on track for year-end 2024.
- R&D expenses $17.9M vs $27.2M; G&A $7.6M vs $7.8M; legal accrual $4.1M from DOJ investigation.
- Plan to begin dosing ATH-1105 in ALS patients in 2025; preclinical data supports HGF-modulating mechanism.

## SEC filing metadata
- accession: 0000950170-24-123324
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017024123324/0000950170-24-123324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017024123324/atha-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123324
- JSON: https://secwatch.observer/filing/0000950170-24-123324.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123324.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.